Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults.
| Autor: | Hsiao A; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA. Electronic address: Amber.Hyman@kp.org., Lewis N; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA., Hansen J; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA., Timbol J; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA., Suaya JA; Heller School, Brandeis University, Waltham, MA, USA., Alexander-Parrish R; Pfizer Vaccine Medicines Development & Scientific Clinical Affairs, Collegeville, PA, USA., Grant LR; Pfizer Vaccine Medicines Development & Scientific Clinical Affairs, Collegeville, PA, USA., Gessner BD; Pfizer Vaccine Medicines Development & Scientific Clinical Affairs, Collegeville, PA, USA., Klein NP; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Vaccine [Vaccine] 2025 Jan 12; Vol. 44, pp. 126543. Date of Electronic Publication: 2024 Dec 04. |
| DOI: | 10.1016/j.vaccine.2024.126543 |
| Abstrakt: | Background: In 2014, the Advisory Committee on Immunization Practices recommended routine use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults age ≥ 65 years. Incidence of most PCV13-serotype cases declined, however serotype 3 cases have persisted. We estimated PCV13 vaccine effectiveness (VE) against PCV13-serotypes and serotype 3 invasive pneumococcal disease (IPD) among Kaiser Permanente Northern California (KPNC) adults. Methods: This observational study included adults ≥65 years between September 1, 2014-December 31, 2020. We used active laboratory-based surveillance to identify and serotype all Streptococcus pneumoniae isolates obtained from normally-sterile sites. We estimated the odds ratio (OR) of vaccine-type IPD using conditional logistic regression stratified by age and calendar day, adjusting for sex, age, race, ethnicity, influenza vaccine receipt, 23-valent pneumococcal polysaccharide vaccine receipt since age 65, pneumonia risk factors, healthcare utilization, and KPNC service area. We estimated VE Results: There were 610,576 adults ≥65 years in the study population. By the end of the study period, PCV13 coverage was nearly 80 %. There were 307 IPD cases during the study period, of which 98 (31.9 %) were serotype 3. PCV13 was associated with a VE Conclusions: PCV13 vaccination protected adults ≥65 years against IPD due to PCV13 serotypes. Continued surveillance will be critical in the ≥65-year-old population to assess the impact of higher valent PCVs on IPD serotype distribution, including individual serotypes such as serotype 3. Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Klein reported receiving grants from Sanofi Pasteur, GlaxoSmithKline, Merck, Pfizer, Seqirus, and the US Centers for Disease and Control outside of the submitted work. Dr. Suaya, Ms. Alexander-Parrish, Dr. Grant, and Dr. Gessner reported being employed by Pfizer at the time of this study and have or had ownership interests in Pfizer. No other conflicts were reported. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect